Barclays PLC Has $235,000 Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Barclays PLC raised its stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 275.0% in the 3rd quarter, Holdings Channel.com reports. The fund owned 64,089 shares of the company’s stock after buying an additional 46,997 shares during the quarter. Barclays PLC’s holdings in Pyxis Oncology were worth $235,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Rhumbline Advisers acquired a new position in Pyxis Oncology in the second quarter valued at about $216,000. American Century Companies Inc. increased its holdings in Pyxis Oncology by 56.0% in the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after buying an additional 20,901 shares during the period. Millennium Management LLC raised its position in shares of Pyxis Oncology by 125.3% in the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after buying an additional 743,499 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $65,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $3,462,000. 39.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Pamela Ann Connealy bought 88,850 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were purchased at an average cost of $1.96 per share, with a total value of $174,146.00. Following the acquisition, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.80% of the company’s stock.

Pyxis Oncology Trading Up 2.0 %

NASDAQ:PYXS opened at $1.50 on Tuesday. The stock’s 50-day moving average is $2.09 and its 200-day moving average is $3.03. The stock has a market cap of $89.21 million, a P/E ratio of -1.46 and a beta of 1.06. Pyxis Oncology, Inc. has a 1-year low of $1.39 and a 1-year high of $6.85.

Analysts Set New Price Targets

PYXS has been the subject of several research analyst reports. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Royal Bank of Canada restated an “outperform” rating and set a $8.00 price objective (down from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price (down previously from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. Finally, Stephens began coverage on Pyxis Oncology in a research note on Friday, November 8th. They set an “overweight” rating and a $13.00 target price for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.43.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.